| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | £ 32.67B | £ 31.38B | £ 30.33B | £ 29.32B | £ 24.70B |
| Gross Profit | £ 23.70B | £ 21.90B | £ 21.25B | £ 19.46B | £ 16.34B |
| Operating Income | £ 7.17B | £ 5.66B | £ 6.99B | £ 6.68B | £ 5.41B |
| EBITDA | £ 11.88B | £ 6.67B | £ 9.14B | £ 8.63B | £ 6.45B |
| Net Income | £ 5.72B | £ 2.58B | £ 4.93B | £ 14.96B | £ 4.38B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | £ 3.16B | £ 3.71B | £ 5.69B | £ 7.68B | £ 4.13B |
| Total Assets | £ 61.12B | £ 59.46B | £ 59.01B | £ 60.15B | £ 79.10B |
| Total Debt | £ 17.72B | £ 16.99B | £ 18.02B | £ 20.99B | £ 24.17B |
| Net Debt | £ 14.57B | £ 13.29B | £ 15.08B | £ 17.46B | £ 20.10B |
| Total Liabilities | £ 45.16B | £ 46.38B | £ 46.21B | £ 50.05B | £ 57.76B |
| Stockholders' Equity | £ 16.38B | £ 13.67B | £ 13.35B | £ 10.60B | £ 15.05B |
| Cash Flow | |||||
| Free Cash Flow | £ 5.96B | £ 3.57B | £ 4.42B | £ 5.14B | £ 5.02B |
| Operating Cash Flow | £ 7.30B | £ 6.55B | £ 6.77B | £ 7.40B | £ 7.95B |
| Investing Cash Flow | £ -5.85B | £ -1.23B | £ -1.59B | £ -8.77B | £ -1.78B |
| Financing Cash Flow | £ -1.63B | £ -4.73B | £ -5.64B | £ 823.00M | £ -7.59B |
GlaxoSmithKline (DE:GS71)
XETRA:GS71
